Aileron Therapeutics Inc (ALRN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Aileron Therapeutics Inc (ALRN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7957
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aileron Therapeutics Inc (Aileron Therapeutics) is a biopharmaceutical company that discovers, develops, and commercializes novel class of therapeutics. The company provides products such as stapled peptide drugs. Its stapled peptides penetrate cells throughout the body and modulate intracellular protein-protein interactions. Aileron Therapeutics’ products are used for therapeutic areas of cancer, inflammation, and endocrine and metabolic diseases. The company’s product candidate ALRN-6924 targets the tumor suppressor protein p53 for the treatment of cancers. It also uses peptide stabilization technology. The company partners with research organizations to provides its products. Aileron Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Aileron Therapeutics Inc (ALRN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 10
Aileron Therapeutics Raises US$30 Million In Series E Financing 12
Aileron Raises US$12 Million In Extended Series D Financing 14
Equity Offering 16
Aileron Therapeutics Plans to Raise up to USD150 Million in Public Offering of Securities 16
Aileron Therapeutics Raises USD56.3 Million in IPO 17
Aileron Therapeutics Raises USD19 Million in Private Placement of Shares 19
Aileron Therapeutics Inc – Key Competitors 20
Aileron Therapeutics Inc – Key Employees 21
Aileron Therapeutics Inc – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Aug 07, 2018: Aileron Therapeutics announces second quarter 2018 financial results 23
May 09, 2018: Aileron Therapeutics Reports First Quarter 2018 Financial Results 25
Apr 02, 2018: Aileron Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results 27
Nov 09, 2017: Aileron Therapeutics Reports Third Quarter 2017 Financial Results 30
Aug 10, 2017: Aileron Therapeutics Reports Second Quarter 2017 Financial Results 32
Corporate Communications 34
Jun 15, 2017: Aileron Therapeutics Appoints Donald Dougherty as Senior Vice President and Chief Financial Officer 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aileron Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 10
Aileron Therapeutics Raises US$30 Million In Series E Financing 12
Aileron Raises US$12 Million In Extended Series D Financing 14
Aileron Therapeutics Plans to Raise up to USD150 Million in Public Offering of Securities 16
Aileron Therapeutics Raises USD56.3 Million in IPO 17
Aileron Therapeutics Raises USD19 Million in Private Placement of Shares 19
Aileron Therapeutics Inc, Key Competitors 20
Aileron Therapeutics Inc, Key Employees 21

List of Figures
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Aileron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Aileron Therapeutics Inc (ALRN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Quality Systems Inc (QSII)-医療機器分野:企業M&A・提携分析
    Summary Quality Systems Inc (QSI) is a healthcare technology company that develops and markets practice management and electronic health records solutions. The company’s solutions comprise ambulatory solutions, population health management and analytics, RCM services, NextGen consulting services, in …
  • Hudson’s Bay Company:企業の戦略・SWOT・財務情報
    Hudson's Bay Company - Strategy, SWOT and Corporate Finance Report Summary Hudson's Bay Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Prismic Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Prismic Pharmaceuticals Inc (Prismic Pharmaceuticals) is a pharmaceutical company that provides research and development of prescription drugs which has unique safety profiles. The company develops drugs for inflammatory diseases and oxidative stress disorders. It pipeline products are used …
  • Hotel Leela Venture Limited:戦略・SWOT・企業財務分析
    Hotel Leela Venture Limited - Strategy, SWOT and Corporate Finance Report Summary Hotel Leela Venture Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Shri Lakshmi Defence Solutions Ltd.:企業の戦略・SWOT・財務情報
    Shri Lakshmi Defence Solutions Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shri Lakshmi Defence Solutions Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Corcept Therapeutics Inc (CORT):企業の財務・戦略的SWOT分析
    Corcept Therapeutics Inc (CORT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Unimedic AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Unimedic AB (Unimedic), formerly Ergobe Pharma AB, a subsidiary of MedCap AB, is a pharmaceutical company which develops, manufactures, distributes and markets pharmaceutical products. The company offers non-licensed, extemporaneous, and licensed pharmaceuticals targeting the therapy areas w …
  • Enerjisa Enerji AS (ENJSA):企業の財務・戦略的SWOT分析
    Enerjisa Enerji AS (ENJSA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Teijin Limited:戦略・SWOT・企業財務分析
    Teijin Limited - Strategy, SWOT and Corporate Finance Report Summary Teijin Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Nuverra Environmental Solutions Inc (NES):石油・ガス:M&Aディール及び事業提携情報
    Summary Nuverra Environmental Solutions Inc (Nuverra), formerly Heckmann Corporation, provides environmental solutions to customers focused on the development and ongoing production of oil and natural gas from shale formations. It provides environmental solutions, including delivery, collection, tre …
  • Mediacom Communications Corp:企業の戦略的SWOT分析
    Mediacom Communications Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Idorsia Pharmaceutical Ltd (IDIA):製薬・医療:M&Aディール及び事業提携情報
    Summary Idorsia Pharmaceutical Ltd (Idorsia) is a manufacturer and developer of medicine that discovers, develops various therapies. The company provides pipeline portfolio such as investigational candidates targeted at the treatment of resistant hypertension, chronic insomnia, vasospasm, and system …
  • Hooker Furniture Corp (HOFT):企業の財務・戦略的SWOT分析
    Hooker Furniture Corp (HOFT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Humanigen Inc (HGEN)-製薬・医療分野:企業M&A・提携分析
    Summary Humanigen Inc(Humanigen) formerly known as KaloBios Pharmaceuticals Inc, is a development stage biopharmaceutical company that develops medicines for neglected and rare diseases. The company offers benznidazole, a nitroimidazole derivative used for the treatment of Chagas disease, a parasiti …
  • Bactiguard Holding AB (BACTI B):医療機器:M&Aディール及び事業提携情報
    Summary Bactiguard Holding AB (Bactiguard) is a medical device manufacturer which develops and supplies infection protection solutions and antibiotics. The company’s product portfolio includes urinary catheters, foley catheters (BIP Foley catheters), endotracheal tubes and central venous catheters. …
  • Mithra Pharmaceuticals SA (MITRA):製薬・医療:M&Aディール及び事業提携情報
    Summary Mithra Pharmaceuticals SA (Mithra) is a developer and manufacturer of over the counter products and prescription drugs for women’s health and other applications. The company offers products such as estelle, donesta, tibelia, zoreline and myring, among others. Its products are used in the tre …
  • H. Lundbeck AS (LUN):企業の財務・戦略的SWOT分析
    H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • VeriFone Systems Inc:企業の戦略・SWOT・財務情報
    VeriFone Systems Inc - Strategy, SWOT and Corporate Finance Report Summary VeriFone Systems Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Duke Energy Corp:企業の発電所・SWOT分析2018
    Duke Energy Corp - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (e …
  • KCA Deutag Alpha Ltd:企業の戦略的SWOT分析
    KCA Deutag Alpha Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆